Trevena Inc (TRVN) - Market Valuation

Public company logo of Trevena (TRVN)

The Trevena, Inc. (TRVN) price chart reflects the performance of a business developing advanced treatments for CNS disorders and severe pain, where patent protection ensures sustainable revenue. Current market capitalization stands at 0.00. The company operates within a secure US legal framework, protected by the humanitarian status of medicine. Growth potential is based on the possibility of global implementation of unique formulas following the completion of clinical trials.

TRVN Trevena: Market Capitalization in the range 07/04/2022 - 10/19/2024
Product sample of trevena.com

The investment attractiveness of the Trevena, Inc. (TRVN) business model depends on its ability to scale its market presence. This metric is calculated as the product of the current share price and the total number of issued securities. Analyzing the market capitalization dynamics of Trevena, Inc. (TRVN) allows for an assessment of the asset's liquidity for large institutional funds. Amidst the stagnant adoption of the drug Olinvyk, this metric reflects a critical level of financial stability. A contraction of this value signals rising fiscal risks and limited access to cheap capital.

Key competitors

Market Value Biogen BIIB|Market Value NBIX|RGC: Market Valuation|AXSM: Market Value|ACADIA Pharmaceuticals (ACAD) - Market Value|Market Capitalization XENE|Market Value Viking Therapeutics, Inc.|Market Capitalization SUPN (Supernus Pharmaceuticals, Inc.)|Market Capitalization CPRX|DNLI - Market Value|Harmony Biosciences - Market Valuation|Market Capitalization biohavenpharma.com BHVN|AMLX - Market Value|Market Value TRVI (Trevi Therapeutics Inc)|Praxis Medicines (PRAX) - Market Value|Market Value Anavex Life Sciences Corp (AVXL)|Market Valuation CBLL|PRTA (Prothena Corp) - Market Value|Market Value Alector, Inc. (ALEC)|ANNX (Annexon Biosciences) - Market Value|Market Capitalization OMER (Omeros)|Neurogene Therapeutics (NGNE) - Market Value|ACIU: Market Valuation|VYGR: Market Value|NMRA: Market Capitalization|Market Value Scilex Holding (SCLX)|Market Value Tevogen Bio Holdings, Inc.|Market Capitalization ACOG (Alpha Cognition Corp)|Market Capitalization CGTX|Market Capitalization inhibikase.com (IKT)|Cassava Sciences - Market Valuation|Market Value ASRT|Coya - Market Capitalization|Market Capitalization Vistagen Therapeutics VTGN|ovidrx.com (OVID) - Market Value|Market Capitalization ABOS|CRVO (CervoMed) - Market Capitalization|Market Valuation Alterity Therapeutics Ltd (ATHE)|Market Valuation CLNN (Clene Inc.)|Market Capitalization pepgen.com|Jupiter Neurosciences - Market Valuation|Market Value RLMD (relmada.com)|ANVS - Market Value|Market Value GRCE (Grace Therapeutics, Inc.)|AIFF (Firefly Neuroscience Inc) - Market Valuation|KLTO (Klotho Neurosciences) - Market Value|Market Value NeuroSense Therapeutics Ltd|Market Capitalization RVPH (revivapharma.com)|Market Value MetaVia Inc (MTVA)|NeurAxis Inc. - Market Capitalization|Market Capitalization HSDT (Helius Medical Technologies)|Passage Bio Inc. (PASG) - Market Value|NEUP: Market Valuation|NERV - Market Capitalization|Athira Pharma (ATHA) - Market Value|Addex Therapeutics Ltd. - Market Value|Market Value Alzamend Neuro Inc.|Market Value Cyclerion CYCN|Market Valuation PTIX (Protagenic Therapeutics)|Market Value KTTA|Market Value Cortigent CRGT|Market Value ATXI|Brainstorm Cell Therapeutics, Inc. - Market Capitalization|Market Value Cara Therapeutics Inc|CHRO (Chromocell Therapeutics) - Market Valuation|ELYM (Eliem Therapeutics Inc.) - Market Value|ITCI (Intra-Cellular Therapies Inc.) - Market Capitalization|Market Value Longboard Pharmaceuticals Inc LBPH|Market Value Marinus (MRNS)|NKGen Biotech Corp - Market Capitalization|Market Capitalization NRBO (NeuroBo Pharmaceuticals)|Market Capitalization sagerx.com SAGE|SNPX: Market Valuation|Market Value VIGL (Vigil Neuroscience)|WENA: Market Capitalization|CERE - Market Capitalization